乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Nephrology >

Diabetes

News, opinions and meeting coverage in nephrology.

<乌鸦传媒>FDA Adds Diabetes Warning to Statin Label

WASHINGTON -- The FDA is changing the labeling on statins to include a warning about increased risks of hyperglycemia and transient memory problems, but the agency is no longer recommending routine liver function testing.

<乌鸦传媒>Diabetes Expert Disses Weight-Loss Programs

WASHINGTON -- Community-based weight-loss programs have not been shown to be effective at reducing the incidence of diabetes, so implementing a national program would likely be money down the drain, a diabetes expert said at a symposium on Tuesday.

<乌鸦传媒>Fructose No Substitute for Glucose in Diabetes

NEW YORK -- Although it negates the dumping of glucose directly into the bloodstream, fructose may not be the choice sweetener for diabetics, researchers said here.

<乌鸦传媒>EASD: Gestational Diabetes Guidelines Controversial

LISBON -- International guidelines on screening for gestational diabetes that will likely raise the prevalence of the condition have sparked questions over appropriate diagnostic tools and cost efficacy, researchers said here.

<乌鸦传媒>Cancer Risk Forces Actos Off French, German Markets

Drug regulators in Germany and France have ordered doctors to stop prescribing the type 2 diabetes drug pioglitazone (Actos), following a French study suggesting a heightened risk of bladder cancer.

<乌鸦传媒>Diet, Exercise Sufficient to Reduce Triglycerides

While cholesterol control is often balanced between statins and lifestyle changes, reducing triglycerides can usually be accomplished with diet and lifestyle changes alone, according to a new scientific statement from the American Heart Association.

<乌鸦传媒>Take Rosiglitazone Off the Market, Says FDA Staff

WASHINGTON -- Rosiglitazone (Avandia) should be pulled from the market because of the "serious" cardiovascular risk the diabetes drug poses, which exceeds that of competitor pioglitazone (Actos), FDA staff reviewers again recommended.

<乌鸦传媒>ACC: FDA Announces Review of ACCORD Data

ATLANTA -- The FDA said it will conduct a full review of findings from a study which concluded that neither aggressive lipid-lowering therapy nor tight blood pressure control reduced cardiovascular events in persons with diabetes.

<乌鸦传媒>Stinky Diabetes Drug May Result in Poor Adherence

An immediate-release form of the antidiabetic agent metformin has a dead fish odor that may cause patients to stop taking the drug, clinicians warned.

<乌鸦传媒>FDA Finds Oral Insulin Spray Safe for IND Use

The FDA approved Oral-lyn, an insulin spray treatment for type I and type II diabetes, for its Investigational New Drug program.

<乌鸦传媒>Kidney Disease Raises Risk of Hypoglycemia

WHEELING, W.Va. -- Dangerous hypoglycemic episodes are a significant risk for patients with chronic kidney disease, whether they have diabetes or not, researchers said.

<乌鸦传媒>Weight-Loss Trial Final Report: 52 Pounds of Fat Melted Away

WEST PALM BEACH, Fla. -- The official results are in: My ending weight was 231 pounds -- a loss of 52 pounds from my starting weight of 283 pounds in January 2008.

<乌鸦传媒>Pregnancy Risks Differ for Interracial Couples

STANFORD, Calif. -- The risk for some pregnancy complications may be greater when one partner is white and the other Asian, researchers found.

<乌鸦传媒>Normal Enzyme Levels May Hide Advanced Liver Fibrosis

MILAN, Italy -- Patients with nonalcoholic fatty liver disease but normal alanine aminotransferase (ALT) levels are still at risk of severe hepatic disease, researchers found.

<乌鸦传媒>Herpes Virus Linked to Ketosis-Prone Diabetes

PARIS -- A herpes virus is associated with an atypical form of type 2 diabetes found in people of African origin, researchers said here.

<乌鸦传媒>Boxed Heart Failure Warning Added to Two Diabetes Drugs

ROCKVILLE, Md. -- The makers of rosiglitazone (Avandia) and pioglitazone (Actos), have agreed to add a black box warning to the type 2 diabetes drugs' labels about an increased risk of heart failure, the FDA said today.

<乌鸦传媒>FDA Approves 'Gila Monster' Diabetes Drug

ROCKVILLE, Md.-The FDA announced today it has approved a new injectable diabetes drug synthesized from gila monster saliva, but says the drug should only be used in combination with older oral medications.